Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

Procurement Magazine takes a look back at the biggest news from across the industry over the last seven days, including SAP, ...

It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown ...